|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600125571 |
|
最近更新日期: Date of Last Refreshed on: |
2026-05-28 12:15:57 |
|
注册时间: Date of Registration: |
2026-05-28 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
右美托咪定鼻喷雾改善妊娠丢失患者术后焦虑抑郁的临床及机制研究 |
|
Public title: |
Clinical and Mechanistic Study on the Effect of Dexmedetomidine Nasal Spray on Postoperative Anxiety and Depression in Patients with Pregnancy Loss |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
右美托咪定鼻喷雾改善妊娠丢失患者术后焦虑抑郁的临床及机制研究 |
|
Scientific title: |
Clinical and Mechanistic Study on the Effect of Dexmedetomidine Nasal Spray on Postoperative Anxiety and Depression in Patients with Pregnancy Loss |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
江明 |
研究负责人: |
冯善武 |
|
Applicant: |
Jiang Ming |
Study leader: |
Feng Shanwu |
|
申请注册联系人电话: Applicant telephone: |
+86 139 1296 1506 |
研究负责人电话: Study leader's telephone: |
+86 139 2142 6351 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
jiangmingnjfy@163.com |
研究负责人电子邮件: Study leader's E-mail: |
jiangmingnjfy@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省南京市莫愁路天妃巷123号 |
研究负责人通讯地址: |
江苏省南京市莫愁路天妃巷123号 |
|
Applicant address: |
No. 123, Tianfei Lane, Mochou Road, Nanjing City,Jiangsu |
Study leader's address: |
No. 123, Tianfei Lane, Mochou Road, Nanjing City,Jiangsu |
|
申请注册联系人邮政编码: Applicant postcode: |
21004 |
研究负责人邮政编码: Study leader's postcode: |
21004 |
|
申请人所在单位: |
南京医科大学附属妇产医院(南京市妇幼保健院) |
||
|
Applicant's institution: |
Nanjing Medical University Affiliated Obstetrics and Gynecology Hospital (Nanjing Maternal and Child Health Hospital) |
||
|
研究负责人所在单位: |
南京医科大学附属妇产医院(南京市妇幼保健院) |
||
|
Affiliation of the Leader: |
Nanjing Medical University Affiliated Obstetrics and Gynecology Hospital (Nanjing Maternal and Child Health Hospital) |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2026KY036-002 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南京市妇幼保健院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Nanjing Maternal and Child Health Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-04-09 00:00:00 |
||
|
伦理委员会联系人: |
侯立 |
||
|
Contact Name of the ethic committee: |
Hou Li |
||
|
伦理委员会联系地址: |
江苏省南京市莫愁路天妃巷123号 |
||
|
Contact Address of the ethic committee: |
123 Tianfei Lane, Mochou Road, Nanjing, Jiangsu |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 25 5222 6919 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
南京医科大学附属妇产医院(南京市妇幼保健院) |
||||||||||||||||||||||
|
Primary sponsor: |
Nanjing Medical University Affiliated Maternity Hospital (Nanjing Maternal and Child Health Hospital) |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省南京市莫愁路天妃巷123号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 123, Tianfei Lane, Mochou Road, Nanjing City, Jiangsu Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家卫生健康委能力建设和继续教育中心慢病管理 |
||||||||||||||||||||||
|
Source(s) of funding: |
The National Health Commission's Capacity Building and Continuing Education Center for Chronic Disease Management |
||||||||||||||||||||||
|
Target disease: |
Perinatal anxiety and depression |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
明确右美托咪定鼻喷雾对术后短期及长期(术后第7天、第42天及半年/一年)的焦虑抑郁的影响 |
||||||||||||||||||||||
|
Objectives of Study: |
To clarify the effect of dexmedetomidine nasal spray on anxiety and depression in the short term and long term (on the 7th day, 42nd day and half a year/year after surgery) after the operation |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄18-50岁;2.ASA分级 I或II级;3.拟行清宫术的妊娠丢失女性患者(包括稽留流产、自然流产或空囊妊娠);4.广泛性焦虑障碍量表(Generalized Anxiety Disorder-7,GAD-7)评分≥5分(轻度及以上焦虑);5.签署知情同意书 |
||||||||||||||||||||||
|
Inclusion criteria |
1. women aged 18-50 years old;2. with ASA classification of I or II; 3.who are pregnant and have experienced miscarriage (including missed abortion, spontaneous abortion or empty pregnancy); 4.with a score of >=5 on the Generalized Anxiety Disorder-7 (GAD-7) scale (indicating mild or above levels of anxiety);5.and who have signed the informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1.体重<40 kg或BMI>30 kg/m^2;2.哺乳期患者;3.曾有睡眠呼吸暂停病史者;4.目前采用阿片类或非阿片类镇痛药控制疼痛者;5.目前服用其他可影响镇静镇痛反应的药物,如中枢α肾上腺素能药物(可乐定或右美托咪定等)、抗癫痫药、神经安定药、抗抑郁药、抗精神病类药物等;6.3月内使用皮质类固醇者;7.术前心电图异常(QTc延长、频发室早等)及肝肾功能损伤者;8.其他术后排除标准包括:术中出现过敏、支气管痉挛、血流动力学不稳定等麻醉不良事件以及子宫穿孔、肠道损伤等手术相关不良事件等 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Body weight < 40 kg or BMI > 30 kg/m^2; 2. Lactating patients; 3. Those with a history of sleep apnea; 4. Those currently using opioid or non-opioid analgesics for pain control; 5. Those currently taking other drugs that can affect sedation and analgesia responses, such as central α-adrenergic drugs (clonidine or dexmedetomidine, etc.), antiepileptic drugs, neuroleptics, antidepressants, antipsychotic drugs, etc.; 6. Those who have used corticosteroids within 3 months; 7. Preoperative electrocardiogram abnormalities (prolonged QTc, frequent ventricular premature beats, etc.) and liver and kidney function impairment; 8. Other postoperative exclusion criteria include: anesthetic adverse events such as allergy, bronchospasm, hemodynamic instability during surgery, as well as surgery-related adverse events such as uterine perforation and intestinal injury. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-05-31 00:00:00至 To 2029-05-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-05-31 00:00:00 至 To 2029-05-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机方法:采用随机区组设计,由与本研究数据收集和管理分析无关的统计专家,使用 SAS 统计软件包,按试验组与对照组 1:1 的比例产生随机数字; 随机结果密封于顺序编号的信封,保存于研究协调员处; |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Randomization method: A randomized block design was adopted. Statistical experts, who were not involved in the data collection, management, and analysis of this study, used the SAS statistical software package to generate random numbers in a 1:1 ratio between the experimental group and the control group. The random results were sealed in sequentially numbered envelopes and stored with the research coordinator. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究采用标准化电子病例记录表(eCRF)进行数据采集。所有研究数据(包括基线资料、干预措施、疗效指标和不良事件)将通过eCRF直接录入,并设置逻辑校验与必填项以确保数据完整性。数据管理采用双人独立录入关键变量,并由监查员定期进行源数据核查以保证数据质量。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
This study utilizes standardized electronic Case Report Forms (eCRFs) for data collection. All research data (including baseline characteristics, interventions, efficacy endpoints, and adverse events) will be directly entered into the eCRFs, which incorporate logical checks and mandatory fields to ensure data completeness. For data management, we implement dual independent entry for key variables, with regular source data verification by monitors to maintain data quality. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |